Ampio Pharma Stock Price, News & Analysis

Ampio Pharmaceuticals (NYSE American: AMPE) has announced its poster presentation titled "Pivoting From One to Multiple Production Platforms to Treat COVID" at the 2021 International Society for Pharmaceutical Engineers (ISPE) Annual Meeting and Expo in Boston from November 1 to 3, 2021. The presentation will take place on November 2, 2021, from 10:30 am to 12:00 pm ET. It highlights Ampio's innovative expansion of its manufacturing capabilities to produce its drug Ampion for COVID-19 treatment after reprogramming its facility within four months.

Ampio Pharmaceuticals (NYSE American: AMPE) will participate in one-on-one meetings with institutional investors at the Alliance Global Partners' Virtual Summer Healthcare Symposium on June 17, 2021. This event is by invitation only, and no webcast will be available. Ampio focuses on immunology-based therapies for inflammatory conditions, with its lead drug Ampion™ backed by a strong patent portfolio, ensuring market exclusivity until 2035 upon FDA approval. The company emphasizes its commitment to advancing treatment options amid growing clinical demand.

Ampio Pharmaceuticals (AMPE) announced its participation in the 23rd International Congress of the International Society for Aerosols in Medicine (ISAM) from May 22-26, 2021, in Boise, Idaho. The company will present a poster titled "Regulatory Decisions during COVID-19: Efficient Nonclinical Inhalation Toxicology for a Clinical Program." The poster focuses on the results from the AP-014 Phase I trial, showing that inhaled Ampion reduced COVID-19 respiratory distress mortality by 78% compared to standard care. Ampio aims to advance inhaled therapies amidst the ongoing pandemic.

Ampio Pharmaceuticals (AMPE) announced IRB approval for its AP-018 Phase I trial, focusing on inhaled Ampion™ for patients with prolonged respiratory symptoms from long COVID. This study will assess safety and efficacy among 30 participants with confirmed COVID-19 diagnoses experiencing at least two symptoms. The trial aims to address a significant medical need, as 3 to 10 million individuals face debilitating long COVID effects. Previous trials showed Ampion reduced all-cause mortality by 78% in COVID-19 respiratory distress. The primary endpoint will be tracking adverse events over 60 days.

Ampio Pharmaceuticals (AMPE) reported its Q1 2021 financial results, highlighting progress in its therapeutic platform. Key achievements include FDA feedback allowing flexibility for the AP-013 Phase III trial in osteoarthritis and promising results from the AP-014 Phase I trial for COVID-19, which showed a 78% reduction in mortality rates compared to standard care. Financially, the company’s cash reserves were $15.8 million, while R&D expenses decreased to $2.3 million. Despite a net loss of $3.7 million, the company aims to sustain operations through mid-2022.

Ampio Pharmaceuticals (AMPE) announced a positive response from the FDA regarding its AP-013 Phase III trial for Ampion™, an anti-inflammatory treatment for severe osteoarthritis of the knee. The FDA's guidance will assist the company in maintaining its Special Protocol Assessment (SPA) as they consider future paths for the trial. Additionally, Ampio reported successful results from its AP-014 Phase I trial of inhaled Ampion for COVID-19, showing reduced mortality rates. Upcoming details will be shared during the earnings call on May 5, 2021.

Ampio Pharmaceuticals (NYSE American: AMPE) announced positive results from its AP-014 Phase I trial of inhaled Ampion for treating respiratory distress in COVID-19 patients. The study achieved a significant 78% reduction in all-cause mortality compared to Standard of Care (SOC), with only 5% mortality in the Ampion group versus 24% in SOC. Patients receiving Ampion also had shorter hospital stays by 4 days and better clinical improvement. The company plans to begin Phase II trials based on these results, aiming for Emergency Use Authorization if efficacy is confirmed.

Ampio Pharmaceuticals (AMPE) announced a conference call to discuss its financial results for Q1 2021 on May 5, 2021, at 4:30 PM EDT. The company focuses on immunology-based therapies for inflammatory conditions, notably its lead drug, Ampion, which has patent protection through 2035 and may gain 12-year FDA market exclusivity post-approval. The call will cover financial metrics and strategic updates, available via the company website for future reference.

Ampio Pharmaceuticals (AMPE) announced pre-clinical research showing that its lead drug candidate, Ampion, mimics the anti-inflammatory effects of dexamethasone without significant adverse effects. The study found that Ampion regulates 102 inflammation-associated genes similarly to dexamethasone, while also differing in 30 key transcripts, indicating distinct mechanisms of action. This research supports ongoing clinical investigations into Ampion as a novel treatment for inflammatory conditions.